3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Small Cell Lung Carcinoma
63
Leukemia, Myeloid, Acute
14
Carcinoma, Non-Small-Cell Lung
14
Lung Neoplasms
11
Lymphoma, Non-Hodgkin
9
Lymphoma, Large B-Cell, Diffuse
9
Recurrence
8
Neoplasms
8
Parkinson Disease 4, Autosomal Dominant Lewy Body
6
Lymphoma
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Carcinoma, Small Cell
4
Ovarian Neoplasms
3
Leukemia
3
Hodgkin Disease
3
Extensive Stage Small Cell Lung Cancer
3
Small Cell Lung Cancer Extensive Stage
2
SCLC
2
Osteosarcoma
2
Neoplasm Metastasis
2
Lymphoma, B-Cell
2
Lymphatic Diseases
2
Immunoproliferative Disorders
2
Hematologic Diseases
2
Glioblastoma
2
Ependymoma
2
Advanced Solid Tumors
2
Widespread Small Cell Lung Cancer
1
Unresectable Locally Advanced or Metastatic Solid Tumors
1
Squamous Cell Carcinoma of Head and Neck
1
Interventions
enzalutamide
5
abiraterone
3
Prednisone
3
Docetaxel
3
Abiraterone Acetate
3
relugolix
1
pembrolizumab
1
onvansertib
1
olaparib
1
lenvatinib
1
inavolisib
1
belzutifan
1
apalutamide
1
abemaciclib
1
Prednisolone
1
PF06821497
1
Methylprednisolone
1
Lutetium-177
1
Lutetium
1
Gonadotropin-Releasing Hormone
1
Etoposide
1
Dexamethasone
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Metastatic Castration-Resistant Prostate Cancer
×
Etoposide
×
Clear all
NCT02861573
2026-02-17
KEYNOTE-365
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
1,200 enrolled